This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2024. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.
We do not have any donee information for the donee General Hospital Corporation d/b/a Massachusetts General Hospital in our system.
Cause area | Count | Median | Mean | Minimum | 10th percentile | 20th percentile | 30th percentile | 40th percentile | 50th percentile | 60th percentile | 70th percentile | 80th percentile | 90th percentile | Maximum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall | 52 | 542,398 | 1,767,029 | -2,166,651 | 0 | 100,000 | 100,000 | 100,000 | 542,398 | 750,001 | 1,277,895 | 2,586,883 | 4,475,028 | 22,751,777 |
Global health | 49 | 600,000 | 1,794,422 | -2,166,651 | 0 | 100,000 | 100,000 | 100,000 | 600,000 | 750,001 | 1,277,895 | 2,586,883 | 4,767,989 | 22,751,777 |
Nutrition | 2 | 100,000 | 1,929,406 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 3,758,812 | 3,758,812 | 3,758,812 | 3,758,812 | 3,758,812 |
Family planning | 1 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 |
Donor | Total | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bill and Melinda Gates Foundation (filter this donee) | 91,885,492.01 | 2,393,392.32 | 2,549,022.00 | 18,427,236.00 | 8,389,266.69 | 8,890,722.00 | 2,878,092.00 | 13,016,460.00 | 9,338,749.00 | 100,000.00 | 5,217,426.00 | 100,000.00 | 20,585,126.00 |
Total | 91,885,492.01 | 2,393,392.32 | 2,549,022.00 | 18,427,236.00 | 8,389,266.69 | 8,890,722.00 | 2,878,092.00 | 13,016,460.00 | 9,338,749.00 | 100,000.00 | 5,217,426.00 | 100,000.00 | 20,585,126.00 |
There are no documents associated with this donee.
Graph of top 10 donors (for donations with known year of donation) by amount, showing the timeframe of donations
Donor | Amount (current USD) | Amount rank (out of 52) | Donation date | Cause area | URL | Influencer | Notes |
---|---|---|---|---|---|---|---|
Bill and Melinda Gates Foundation | 1,085,512.50 | 17 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to enable the rapid development of vaccines for HIV and TB. Global Health Innovation Partnership. Investment start date: 6/22/2015 to end date: 5/31/2021. Grantee name: General Hospital Corporation d/b/a Massachusetts General Hospital; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 1,085,512.50 | 17 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to enable the rapid development of vaccines for HIV and TB. Global Health Innovation Partnership. Investment start date: 6/22/2015 to end date: 5/31/2021. Grantee name: General Hospital Corporation d/b/a Massachusetts General Hospital; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | -52,724.68 | 50 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a project designed to define the baseline status of the immune system immediately before, and during the earliest events in HIV infection, and to define events leading to the development of effective protective immunity; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 275,092.00 | 29 | Global health/Reproductive health care | https://iatiregistry.org/publisher/bmgf | -- | to support an evaluation of the behavioral and contextual barriers to optimal usage of a Uterine Balloon Tamponade (UBT) package, identify the optimal levers for uptake acceleration, and implement an updated the training package; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 1,962,033.00 | 15 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to identify the potential causal role of antibodies in MTB control in vivo in an effort to guide future vaccine design; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 750,001.00 | 21 | Global health/Reproductive health care | https://iatiregistry.org/publisher/bmgf | -- | to support an evaluation of the behavioral and contextual barriers to optimal usage of a Uterine Balloon Tamponade (UBT) package, identify the optimal levers for uptake acceleration, and implement an updated the training package; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | -163,012.00 | 51 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a project designed to define the baseline status of the immune system immediately before, and during the earliest events in HIV infection, and to define events leading to the development of effective protective immunity; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 2,586,883.00 | 11 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to develop a novel set of tools to expedite the development of safe and effective clustered regularly interspaced short palindromic repeats nuclease-based gene drive solutions for genetic control of human malaria vector Anopheles gambiae; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 2,984,509.00 | 10 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to identify unique immune responses in individuals who resist tuberculosis infection to guide future vaccine design; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 1,277,895.00 | 16 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to identify the potential causal role of antibodies in MTB control in vivo in an effort to guide future vaccine design; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Family planning | https://iatiregistry.org/publisher/bmgf | -- | to develop lower cost and more effective female contraceptives by using their cell-based screening platform to identify compounds that target one of the earliest stages of follicle development in the ovary; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 4,848,947.00 | 4 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to define cell immune responses induced by hyperacute and chronic HIV infection to inform vaccine design; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 3,380,465.00 | 8 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to plan for the elimination of cholera transmission in Haiti via the implementation of a package of oral cholera vaccine complemented by water interventions in a specific catchment area with research to document best practices; Aid type: Project-type interventions. Affected countries: Haiti. | |
Bill and Melinda Gates Foundation | 600,000.00 | 25 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to enable the rapid development of vaccines for HIV and TB. Global Health Innovation Partnership. Investment start date: 6/22/2015 to end date: 5/31/2021. Grantee name: General Hospital Corporation d/b/a Massachusetts General Hospital; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 600,000.00 | 25 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to enable the rapid development of vaccines for HIV and TB. Global Health Innovation Partnership. Investment start date: 6/22/2015 to end date: 5/31/2021. Grantee name: General Hospital Corporation d/b/a Massachusetts General Hospital; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 2,048,537.00 | 13 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a genetic approach to optimizing the antigenicity of HIV-1 envelope immunogens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 1,996,999.00 | 14 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to test the potential use of adjuvant anti-angiogenic and anti-fibrotic treatment to improve drug delivery and increase the efficacy of existing tuberculosis drugs, potentially shortening treatment duration, and thereby improving and simplifying tuberculo; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 3,758,812.00 | 7 | Nutrition/basic nutrition | https://iatiregistry.org/publisher/bmgf | -- | to provide a minimally invasive means for obtaining detailed information on infantile intestinal tissue that is needed for the development of effective environmental enteropathy (EE) interventions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Nutrition/basic nutrition | https://iatiregistry.org/publisher/bmgf | -- | to better treat environmental enteropathy and other potentially deadly childhood diseases caused by enteric pathogens such as Escherichia coli by isolating and/or engineering selective bacteriophage (viruses that infect bacteria); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 750,000.00 | 22 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to enable the rapid development of vaccines for HIV and TB. Global Health Innovation Partnership. Investment start date: 6/22/2015 to end date: 5/31/2021. Grantee name: General Hospital Corporation d/b/a Massachusetts General Hospital; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 750,000.00 | 22 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to enable the rapid development of vaccines for HIV and TB. Global Health Innovation Partnership. Investment start date: 6/22/2015 to end date: 5/31/2021. Grantee name: General Hospital Corporation d/b/a Massachusetts General Hospital; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 1,033,649.00 | 19 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to develop an ultra-rapid freezing protocol using quartz microcapillary tubes in order to provide a more immediate cryopreservation method that can be quickly delivered to the malaria community; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | -193.31 | 47 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to develop a new class of potentially effective antimalarial drugs by evaluating inhibitors of tRNA-synthetases, which are enzymes that are essential for survival of the malaria parasite; Aid type: Project-type interventions. Affected regions: South of Sahara. | |
Bill and Melinda Gates Foundation | 20,000.00 | 46 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a study that will determine the need and nature of adherence interventions that may be required to expand treatment to people with early HIV disease as an essential step to reducing HIV incidence; Aid type: Project-type interventions. Affected regions: South of Sahara. | |
Bill and Melinda Gates Foundation | -20,000.00 | 48 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to prevent HIV transmission through improving adherence to pre-exposure prophylaxis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 42,487.06 | 45 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a project designed to define the baseline status of the immune system immediately before, and during the earliest events in HIV infection, and to define events leading to the development of effective protective immunity; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | -42,487.06 | 49 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to use population based studies of immune responses, viral evolution and host genetics to achieve effective immunogen design for a global HIV vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 3,109,314.00 | 9 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to apply and further develop a set of tools to define vaccine signatures associated with protection from infection to guide future vaccine design; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 4,767,989.00 | 5 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a study that will determine the need and nature of adherence interventions that may be required to expand treatment to people with early HIV disease as an essential step to reducing HIV incidence; Aid type: Project-type interventions. Affected regions: South of Sahara. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/basic health care | https://iatiregistry.org/publisher/bmgf | -- | to improve detection of abnormal brain development in low-income settings by using a non-invasive handheld optical coherence tomography device to measure the thickness of the retina over the first five years of life; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 652,050.00 | 24 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a project designed to define the baseline status of the immune system immediately before, and during the earliest events in HIV infection, and to define events leading to the development of effective protective immunity; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 78,246.00 | 44 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to prevent HIV transmission through improving adherence to pre-exposure prophylaxis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 183,123.00 | 30 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a genetic approach to optimizing the antigenicity of HIV-1 envelope immunogens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 2,436,233.00 | 12 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a genetic approach to optimizing the antigenicity of HIV-1 envelope immunogens; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 341,859.00 | 28 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to define, induce, and evaluate the protection afforded by potent innate immune-recruiting antibodies..; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to develop a new class of potentially effective antimalarial drugs by evaluating inhibitors of tRNA-synthetases, which are enzymes that are essential for survival of the malaria parasite; Aid type: Project-type interventions. Affected regions: South of Sahara. | |
Bill and Melinda Gates Foundation | 12,916,460.00 | 2 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support a project designed to define the baseline status of the immune system immediately before, and during the earliest events in HIV infection, and to define events leading to the development of effective protective immunity; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to develop a microfluidic device that can be used to screen anti-malarial drugs for the development of drug resistance with single cell resolution.; Aid type: Project-type interventions. Affected regions: South of Sahara. | |
Bill and Melinda Gates Foundation | 974,995.00 | 20 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to research the impact of antiangiogenic treatment on the efficacy of treatment for TB - Exploring vascular homeostatis in TB persistence; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 7,963,754.00 | 3 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to define, induce, and evaluate the protection afforded by potent innate immune-recruiting antibodies..; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to develop a cell phone system that can aid in vaccination campaigns in developing countries.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to test whether pre-treating the skin at the site of vaccination with an infrared laser light to stimulate antigen-presenting cells will result in a stronger immune response to the polio vaccination.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/basic health care | https://iatiregistry.org/publisher/bmgf | -- | to develop a portable, low-cost mobile-phone-based near-infrared camera for monitoring brain injury in neonates.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to identify and characterize individual cells latently infected with HIV for use as markers to target and eliminate HIV-infected cells.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/Medical research | https://iatiregistry.org/publisher/bmgf | -- | to attempt to reverse engineer in vitro G-protein coupled receptors (GPCRs), which usually are used by the human body to sense light, odors, tastes and hormones, to detect selected parasite biomarkers; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 542,398.00 | 27 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to research the impact of antiangiogenic treatment on the efficacy of treatment for TB - Exploring vascular homeostatis in TB persistence; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to investigate whether using oral supplementation of intestinal alkaline phosphatase (IAP), will prevent or cure infection by pathogenic bacteria, leading to a universal strategy against diarrheal diseases.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 4,475,028.00 | 6 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to prevent HIV transmission through improving adherence to pre-exposure prophylaxis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to test whether injection of a vaccine into laser-exposed skin can significantly enhance immune responses stimulated by the vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 100,000.00 | 31 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to design a conjugate which will attach to the GP63 enzyme of the Leishmania parasite, creating a lightactivatable, non-toxic chemical therapy that will be activated by a light source, killing the parasite but leaving surrounding cells intact; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | -2,166,651.00 | 52 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to use population based studies of immune responses, viral evolution and host genetics to achieve effective immunogen design for a global HIV vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
Bill and Melinda Gates Foundation | 22,751,777.00 | 1 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to use population based studies of immune responses, viral evolution and host genetics to achieve effective immunogen design for a global HIV vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |